The 2025 Italian Budget Law had delivered to Italian pharmaceutical wholesalers the first concrete sign of recognition after nearly fifteen years: the 0.65% additional margin on the public price net of VAT, a recognition bringing the total from 3% to 3.65%, which ADF and Federfarma Servizi (Italian wholesaler associations) had described, in their joint statement of 9 January 2025, as “the first step of a structural path”. On the 2026 horizon the message was clear: the historic cut from 6.65% to 3% imposed by Law 122/2010 was slowly starting to be reintegrated.
That message cracked on 9 February 2026, when the TAR Lazio (Italy’s Regional Administrative Court for Lazio) published its ruling on the appeal filed by Doc Generici, upholding it. The operative part is explicit: the 0.65% additional margin does not apply to generic (equivalent) drugs. According to the judges, article 324 of Law 207/2024 has “dispositive and prescriptive” force and “can refer only to the share applicable to originator drugs”. For wholesalers, the result is simple to tell and painful to absorb: on the volume share represented by generics, the margin remains at 3%; the addition only applies to branded.
The estimated economic impact is approximately €20 million per year of lost revenue for Italian intermediate distributors. In a sector with EBITDA profitability of 1.5% (Polimi Contract Logistics Healthcare Observatory 2025) and 47% of operators below the 2% threshold, it’s a number that weighs.
A note for non-Italian readers: this is one of those moments where the Italian regulated-margin system, specific to Italian pharmaceutical wholesale, produces tensions that don’t have direct equivalents in most other EU markets, where wholesale margin is contractually negotiated. The court ruling is a typical Italian-system event whose effects are nonetheless concrete and quantifiable.
This article reconstructs the ruling, the legal reasoning behind it, the economic and operational consequences for a DIF wholesaler, and the plausible moves in the coming months.
The regulatory framework: how we get to 3.65%
To read the ruling we need to reconstruct the regulatory path that led to the 2025 Budget Law. The structural cut dates back fifteen years: with article 11 paragraph 6 of Decree-Law 78/2010 converted into Law 122/2010, the margin of pharmaceutical wholesalers was brought from 6.65% to 3% of the public price net of VAT. Simultaneously, pharmacies’ margin rose from 26.7% to 30.35% — the overall value transferred downstream remained unchanged, but the wholesale share was halved.
The supply chain lived for a decade with margins insufficient even to cover typical operating costs, while regulatory requirements (GDP, FMD, traceability) and personnel costs (Italian Logistics National Collective Agreement 2024 renewals with ~10% tariff increases spread over three years) rose structurally.
The 2025 Budget Law — article 324 of the 2024 Budget Law (Law 207/2024) — partially recognised the imbalance. The new distribution of the public price is:
- Pharmaceutical industry: 66% (down from previous 66.65%)
- Intermediate distributors: 3.65% (3% base + 0.65% additional margin)
- Pharmacies: 30.35% (unchanged)
The salient feature of the 0.65% is that it was declared “non-contestable and non-transferable”: it cannot be transferred as a discount to any other actor in the supply chain, and in particular cannot be “reabsorbed” through purchase or marketing rewards granted by industry. Distributor associations had insisted on this point precisely because the risk was that the recognition would be hollowed out downstream.
The total additional resources for DIF were estimated at approximately €70 million per year, to which was added — for 2026 and 2027 — an integration of €0.05 per package distributed to territorial pharmacies, with a cap of €50 million per year.
The 9 February 2026 ruling: the legal point
The TAR Lazio ruled on the appeal filed by Doc Generici, one of the main Italian companies active in the equivalents segment. The legal question at the centre: was the extension of the 0.65% additional margin to generics, contained in an AIFA (Italian Medicines Agency) circular, legitimate compared to the text of Law 207/2024?
The judges’ answer is no. The ruling has three cornerstones:
First, article 324 has “dispositive and prescriptive” force — meaning the legislator bindingly disposed the new distribution, and the AIFA circular could not expand its scope of application interpretively.
Second, the 0.65% addition — textually — “can refer only to the share applicable to originator drugs”. Generics, which have a structurally different price mechanism (alignment to reference price, price transparency to industry), remain outside the perimeter.
Third — direct consequence — the AIFA circular extending the 0.65% to generics is annulled. On generics, wholesalers continue to operate at 3% margin without addition.
The ruling is not yet final. Two paths remain open. The first is an appeal to the Italian Council of State by AIFA and/or the Ministry of Health, which could overturn the decision or refer it to wider sections. The second — more likely, in terms of timing and effectiveness — is a new legislative intervention reformulating article 324 to close the interpretive doubt, explicitly including (or excluding) generics.
Pending one of these two moves, the operational status quo is clear: the addition only applies to branded.
The economic impact: the missing €20 million
The figure circulating in the sector is approximately €20 million per year of total lost revenue for Italian intermediate distribution. The figure is approximate but well-founded: generics represent a significant — not majority, but structurally growing — share of the value of Italian NHS distribution. On that share the 0.65% translates into millions of euros of lost margin at the aggregate level.
For the single wholesaler, the impact depends on the branded/generics mix of their portfolio. A regional intermediate distributor with €25 million in annual NHS revenue, with a 70% branded / 30% generics mix, sees the effect like this:
Annual NHS branded: €17,500,000
- Old margin (3%): €525,000
- New margin (3.65%): €638,750
- Positive Δ Budget 2025: +€113,750/year
Annual NHS generics: €7,500,000
- Old margin (3%): €225,000
- Expected margin post-AIFA circular (3.65%): €273,750
- Actual margin post-TAR (3%): €225,000
- Δ vs expectation: -€48,750/year
Net 2025 Budget effect after TAR: +€65,000/yearOn a typical EBITDA for a distributor of this size (1.5% × €25M = approximately €375,000), €48,750 of foregone margin means 13% less EBITDA versus the expectation after the regulatory update. For an already structurally stretched sector, it’s a significant correction.
Add that the generics share in Italian distribution is growing for demographic and public-spending sustainability reasons: every year the calculation base of the “missing €48,750” becomes a bit wider.
The operational case: how the cluster margin calculation changes
For the intermediate distributor that has implemented a pharmacy-by-pharmacy cost-to-serve system, the TAR ruling requires a concrete adjustment to the calculation model. Before 9 February 2026, the standard percentage margin to apply to the basket was 3.65%. From today on, it must be split:
- 3.65% margin on the branded share of the basket
- 3% margin on the generics share of the basket
To estimate the annual gross margin produced by a pharmacy, it therefore becomes necessary to know — at least approximately — the branded/generics mix of that pharmacy’s basket. The ideal granularity is the single pack, but an estimate by therapeutic category (e.g. pharmacies with strong cardiovascular specialisation, with high generics penetration, have a mix typically more skewed towards 3%) is already operational.
The effect on the portfolio map is predictable: pharmacies with high generics penetration drop in net profitability ranking. A pharmacy that was previously marginal (grey zone between “profitable” and “loss-making”) may now be structurally loss-making. Not because the pharmacy has changed: the margin calculation rule has changed.
The update of the Optivo Margin Calculator already allows entering the actual applicable margin — just use 3% instead of 3.65% to simulate the effect of the ruling on a cluster of high-generics-vocation pharmacies, or weight the two percentages according to the real mix.
Plausible moves in the coming months
Based on the historical precedent of similar pharmaceutical-sector controversies, the next probable steps are:
Appeal to the Italian Council of State by AIFA and/or the Ministry of Health. The decision to appeal is political as well as technical: the government supported the 2025 Budget Law also with wholesalers, and the ruling is a direct setback to the original design. Probability: high. Timing: 12-18 months for a definitive outcome.
New legislative intervention clarifying the extension of the 0.65% to generics (or explicitly excluding it to consolidate the current situation). Probability: medium-high, especially if the Council of State appeal looks long or uncertain. Possible vehicle: amendment to the first useful provision (Health Decree, 2026 Budget Law, Milleproroghe decree). Timing: 3-9 months.
Alternative compensation for the sector — changes to other components (e.g. the €0.05/pack 2026-2027 integration, subject to interpretations still open) — is plan B if the first two paths remain blocked. Timing: variable.
In all three hypotheses, the intermediate distributor finds itself in the position of operating with regulatory uncertainty that directly impacts 12-month planning. The most reasonable thing, in operations of this scope, is not to base the 2026 economic projections on a full 3.65% margin: write budgets and P&Ls “as is” — on the post-ruling situation — and keep the +0.65% on generics as a potential upside revised in-year.
Planning implications: generics clusters under the lens
For intermediate distributors with a strategic planning system — those using simulations and progressive route recomposition as described in the pillar on pharmaceutical fixed-route optimisation — the ruling requires verification on geographic clusters with strong generics vocation. Typically: areas with public healthcare structures (Italian local health authorities, hospitals) that push on DPC (distribution on behalf of NHS) and that translate to distributors a delivery composition with high generics percentage; or clusters of municipal pharmacies with aggressive pricing policies on equivalents.
On these clusters, the effective per-delivery margin drops. Cost-to-serve does not. Net margin reduces. If before 9 February 2026 the zone was marginally sustainable, today it may not be.
The standard simulation model — which has frequency, basket, geography as variables — must be enriched with a branded/generics mix variable. For our DIF clients we are working in this direction, and it’s one of the most significant modifications to the cost-to-serve model in the last 12 months.
Frequently asked questions
Is the TAR Lazio ruling final?
No. It’s a first-instance administrative justice ruling, subject to possible appeal to the Italian Council of State by AIFA and/or the Ministry of Health. Until a Council of State ruling or new legislative intervention, the operational status is the one fixed by the TAR: the 0.65% applies only to branded drugs.
How much is the 0.65% on generics concretely worth for Italian DIF?
The estimated impact is approximately €20 million of total lost annual revenue. The figure is approximate and depends on the evolution of the branded/generics mix in NHS distribution.
Does the 0.65% on branded remain fully non-transferable?
Yes. The “non-contestable and non-transferable” feature of the 0.65% — not transferable as a discount to other supply chain actors — has not been touched by the ruling. It applies entirely on the branded share.
What should intermediate distributors do immediately?
Three things. First, update the margin calculation model on high-generics clusters (3% instead of 3.65%). Second, recalculate cost-to-serve on pharmacies with baskets skewed toward generics, where net margin can drop significantly. Third, monitor developments of the Council of State appeal and any new legislative interventions to update budget projections.
Is the Optivo calculator already updated to this situation?
Yes. The Pharmacy Margin Calculator allows entering the applicable percentage margin as a modifiable parameter: to simulate a cluster with strong generics vocation, simply set 3% instead of 3.65%. For a customised calculation on your portfolio’s branded/generics mix composition, talk to our team.
In summary
The TAR Lazio ruling of 9 February 2026 has partly rewritten the maths of the 2025 Italian Budget Law for pharmaceutical intermediate distributors. The 0.65% additional margin, recognised as “the first step of a structural path”, remains on all branded but falls on generics, subtracting from the sector an estimated €20 million per year.
On the regulatory plane, two paths remain open: appeal to the Council of State (long timing, uncertain outcome) and a new legislative intervention (faster, politically sensitive). Operationally, in the meantime, the intermediate distributor finds itself having to manage a double margin rule — 3.65% on branded, 3% on generics — that has non-trivial effects on pharmacy profitability ranking and on geographic clusters with strong equivalents vocation.
For those with a strategic planning and cost-to-serve system, updating the model is the concrete thing to do in the coming weeks. If you want to understand how the ruling’s effect reflects on your real pharmacy portfolio — which clusters drop in ranking, where it makes sense to renegotiate conditions — talk to our team. Three months of POD and product mix data are enough to build the updated projection.